Exact Sciences' (NASDAQ: EXAS ) phase 3 trial for its colon cancer detection test passed, but the stock dropped 20%. What gives? In this video, David Williamson goes into the details of Exact Sciences' DNA-based test. The overall effectiveness of the Cologuard test was 92%. However, the detection rate was 42%, less than colonoscopy, and the 87% overall accuracy rate leads to a higher false positive rate than most doctors would like to see. Is Exact Sciences doomed? Not really -- it has $100 million in the bank. It may be a takeover target, and David sees Intuitive Surgical (NASDAQ: ISRG ) as a possible buyer.
Are stories of this demise greatly exaggerated?
Recently, some investors have questioned Intuitive Surgical's future. However, Intuitive Surgical expert Karl Thiel believes a visible path to long-term growth persists. Will Intuitive capitalize or be crushed by unforeseen pitfalls? His report highlights all of the key opportunities and risks facing the company -- and includes a full year of ongoing updates as key news hits -- so be sure to claim your copy by clicking here now.